SANUWAVE Health, Inc. (SNWV)
| Market Cap | 126.92M -50.7% |
| Revenue (ttm) | 44.34M +22.5% |
| Net Income | 16.49M |
| EPS | 0.92 |
| Shares Out | 8.60M |
| PE Ratio | 16.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,404 |
| Open | 15.38 |
| Previous Close | 15.39 |
| Day's Range | 14.67 - 15.56 |
| 52-Week Range | 14.67 - 46.59 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 40.00 (+171.0%) |
| Earnings Date | May 12, 2026 |
About SNWV
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for SNWV stock is "Strong Buy" and the 12-month stock price target is $40.0.
News
SANUWAVE Health Earnings Call Transcript: Q1 2026
Record Q1 revenue and strong consumables growth were achieved despite a market freeze from CMS pricing changes. Guidance for 2026 remains robust, with expectations for a stronger second half driven by seasonality and large account engagement.
SANUWAVE Health Quarterly report: Q1 2026
SANUWAVE Health has published its Q1 2026 quarterly earnings report on May 13, 2026.
SANUWAVE Health Earnings release: Q1 2026
SANUWAVE Health released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
SANUWAVE Health Slides: Q1 2026
SANUWAVE Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Sanuwave Health reports Q1 EPS (17c) vs (72c) last year
Reports Q1 revenue $9.6M vs $9.3M last year. “The seemingly ubiquitous question in advanced wound care during Q1 was ‘When is the turn coming and when will the recovery start?’”…
Sanuwave Health sees Q2 revenue $11.1M-$11.6M, one estimate $11.5M
17:03 EDT Sanuwave Health (SNWV) sees Q2 revenue $11.1M-$11.6M, one estimate $11.5M
Sanuwave Health backs FY26 revenue view $51M-$55M, one estimate $51.35M
17:03 EDT Sanuwave Health (SNWV) backs FY26 revenue view $51M-$55M, one estimate $51.35M
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Q1 2026 revenues were $9.6 million , up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will h...
SANUWAVE Health Proxy statement: Proxy filing
SANUWAVE Health filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
SANUWAVE Health Proxy statement: Proxy filing
SANUWAVE Health filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Sanuwave Health narrows Q1 revenue view to $9.6M-$9.7M from $9.6M-$10.3M
Q1 revenue consensus $9.84M. “At the end of Q1 the Company saw several good-sized deals (all of which remain live) slide out of the quarter and this brought us in…
Sanuwave Health price target lowered to $47 from $53 at Roth Capital
Roth Capital analyst Kyle Bauser lowered the firm’s price target on Sanuwave Health (SNWV) to $47 from $53 and keeps a Buy rating on the shares. Despite an FY26 revenue…
SANUWAVE Health Earnings Call Transcript: Q4 2025
Record Q4 and full-year revenue growth driven by UltraMIST system sales and consumables, despite industry disruption from CMS reimbursement changes. Strategic channel shift to resellers and strong cash position support 2026 growth outlook of 16%–25%.
SANUWAVE Health Earnings release: Q4 2025
SANUWAVE Health released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
SANUWAVE Health Annual report: Q4 2025
SANUWAVE Health has published its Q4 2025 annual report on March 27, 2026.
SANUWAVE Health Slides: Q4 2025
SANUWAVE Health has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 27, 2026.
Sanuwave Health reports Q4 adjusted EBITDA $4.77M vs $3.66M last year
Reports Q4 revenue $13.4M, up 29.7% year-over-year. “We’re pleased to be, once more, announcing an all-time record quarter for Sanuwave on both revenues and adjusted EBITDA, especially during such cha...
Sanuwave Health sees Q1 revenue $9.6M-$10.3M
17:02 EDT Sanuwave Health (SNWV) sees Q1 revenue $9.6M-$10.3M
Sanuwave Health sees FY26 revenue $51M-$55M
17:03 EDT Sanuwave Health (SNWV) sees FY26 revenue $51M-$55M
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company.
Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will...
Sanuwave Health sees Q4 revenue $13.3M-$13.4M, up 29%-30% y/y
On Friday, the company stated: “Sanuwave Health (SNWV) announced that revenues for the fourth quarter of 2025 are expected to be in the range of $13.3 to $13.4 million, an…
Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Roth Capital views Sanuwave Health’s UltraMIST news as ‘highly favorable’
Roth Capital notes Sanuwave Health (SNWV) announced that its UltraMIST product line had been added to Healogics Wound Care Supply’s group purchasing organization, Healogics iSupply. The collaboration ...